A brief review of the current breast cancer prevention trials and proposals for future trials.

TitleA brief review of the current breast cancer prevention trials and proposals for future trials.
Publication TypeJournal Article
Year of Publication2000
AuthorsCuzick J
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume36
Issue10
Pagination1298-302
Date Published2000 Jun
ISSN0959-8049
KeywordsAdult, Aged, Antineoplastic Agents, Hormonal, Breast Neoplasms, Clinical Trials as Topic, Endometrial Neoplasms, Female, Hot Flashes, Humans, Menstruation Disturbances, Meta-Analysis as Topic, Middle Aged, Raloxifene, Risk Factors, Tamoxifen
Abstract

The available results from breast cancer chemoprevention trials are reviewed. Four trials using tamoxifen have been performed of which three have reported efficacy results. A fifth trial using raloxifene has also been published. The largest tamoxifen trial shows approximately a 50% reduction in breast cancer incidence in the short term, but the two smaller trials have not found any incidence reduction. Greater agreement exists for side-effects - thromboembolic disease and endometrial cancers are raised about 2 to 3-fold when tamoxifen is used for 5 years. The possible reasons for the discrepancy in breast cancer reduction are explored. A review of trial parameters does not clearly explain this difference, and a meta-analysis indicates that all results are compatible with a 42% reduction in short-term incidence. Several important questions remain about the clinical implication of this result, including the effect on mortality, the appropriate risk groups for chemoprevention and the long-term effects on incidence. Continued follow-up of these trials is crucial for resolving these issues.

Alternate JournalEur. J. Cancer
PubMed ID10882870
Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon
Get email updates
Recipes. upcoming classes.